ICAN BioCell iPSThe ICAN BioCell iPS platformThe possibility of developing induced pluripotent stem cells (iPSCs) from adult cells, i.e. cells capable of differentiating into other adult cell types, has revolutionized the study of the molecular mechanisms of human disease. This approach is particularly well suited to diseases of genetic origin. In this case, adult cells, in particular blood cells, are harvested from sick donors carrying genetic mutations.The ICAN BioCell iPS platform aims to develop new cellular models for research into cardiometabolic diseases. It is dedicated to the reprogramming of adult cells into induced pluripotent stem cells and their differentiation into different cell models (cardiomyocytes, endothelial cells, hepatocytes, adipocytes, etc.).See the BioCell iPS charterOur mission: production and genetic modification of iPS cells
- The ICAN BioCell iPS platform specializes in the production and genetic modification of iPSC cells, known as genome editing, and their differentiation into adult cells such as cardiomyocytes, endothelial cells, adipocytes and hepatocytes.
- The ICAN BioCell iPS team is developing more complex humanized models in the form of organoids. These pseudo-tissues called organoids are generated in vitro to form beating heart muscle by combining cardiomyocytes, endothelial cells and cardiac fibroblasts. This cardiac organoid will allow the establishment of complex interactions between these cells and subsequently be able to study certain physiological parameters such as the action potential and the heart rate.
- ICAN BioCell iPS also manages the generation of genetically modified iPSC clones using CRISPR/CAS9 technology, by inserting a corrective template into the genome to remove a mutation, to generate KI (knock-in) by inserting a mutated template into control iPSCs, or KO (knock-out) by non-homologous recombination after cutting.
- The platform also owns a number of iPS lines and models for hypertrophic, dilated and arrhythmogenic cardiomyopathies.
Cardiomyocytes, marquage MLC2a et MLC2VEnothelial cells, CD31 and DAPI labelingiPSC clone immunostained for pluripotency proteinsOur services
- Maintenance of iPSC lines
- Reprogramming human adult cells into iPSCs
- CRISPR/CAS9 genome editing
- Differentiation and characterization of iPSCs
- Training in iPSC culture and differentiation
The platform has an L2 laboratory equipped with
- 4 type II microbiological safety cabinets
- 3 Lynxx systems for passage and maintenance of iPSC lines
- 1 CO2 incubators dedicated to iPSC culture
- 2 CO2 incubator dedicated to the differentiation of iPSCs into mature cells
- 1 tri-gas incubator for reprogramming somatic cells (fibroblasts, PBMCs) into iPSCs
- Cell counter and microscope
Pricing on estimateContact usVincent FONTAINEResponsiblev.fontaine@ihuican.org
01 40 77 81 39Eric VILLARDScientific officerICAN BioCell iPS scientific publications04/2024Generation of CRISPR/Cas9 edited human induced pluripotent stem cell line carrying the heterozygous p.H695VfsX5 frameshift mutation in the exon 10 of the PKP2 gene02/2024Generation of CRISPR-Cas9 edited human induced pluripotent stem cell line carrying BAG3 V468M mutation in its BAG domain28/12/2022Maintenance of methylation profile in imprinting control regions in human induced pluripotent stem cells04/2022Generation of a heterozygous SCN5A knockout human induced pluripotent stem cell line by CRISPR/Cas9 edition01/2022Generation of CRISPR-Cas9 edited human induced pluripotent stem cell line carrying FLNC exon skipping variant21/05/2021Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.2304/2021Generation of iPSC line from MYH7 R403L mutation carrier with severe hypertrophic cardiomyopathy and isogenic CRISPR/Cas9 corrected control11/02/2021Generation of iPSC line from MYH7 R403L mutation carrier with severe hypertrophic cardiomyopathy and isogenic CRISPR/Cas9 corrected control18/06/2017Differential Sarcomere and Electrophysiological Maturation of Human iPSC-Derived Cardiac Myocytes in Monolayer vs. Aggregation-Based Differentiation Protocols21/05/2021Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23Make a donation
